Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analyst view: Gilead has a consensus rating of "Moderate Buy" from 28 analysts (24 buy, 4 hold) with an average 12‑month price target of about $157.35.
• Strategic boost: Gilead completed the ~ $7.8 billion acquisition of Arcellx, securing anito‑cel and strengthening its cell‑therapy pipeline ahead of potential commercial launch, which some technical analysts say could imply significant upside though near‑term volatility may follow.
• Financials & returns: Gilead beat Q results (EPS $1.86 vs $1.83 est.; revenue $7.93B vs $7.68B), set FY2026 guidance of $8.45–$8.85 EPS, and raised its quarterly dividend to $0.82 (annualized $3.28, ~2.5% yield).

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-eight analysts that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and twenty-four have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $157.3462.

A number of equities research analysts have recently weighed in on GILD shares. Deutsche Bank Aktiengesellschaft lifted their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock a "buy" rating in a research report on Wednesday, February 11th. Bank of America set a $162.00 price objective on Gilead Sciences and gave the stock a "buy" rating in a research report on Wednesday, February 11th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $125.00 to $130.00 and gave the stock a "neutral" rating in a research report on Friday, April 17th. Wall Street Zen upgraded Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday, March 14th. Finally, Rothschild & Co Redburn lifted their price target on Gilead Sciences from $159.00 to $170.00 and gave the company a "buy" rating in a research report on Tuesday, February 17th.

Gilead Sciences Price Performance

Shares of GILD stock opened at $129.26 on Wednesday. The firm has a market cap of $160.44 billion, a P/E ratio of 19.09, a P/E/G ratio of 1.69 and a beta of 0.39. Gilead Sciences has a fifty-two week low of $95.29 and a fifty-two week high of $157.29. The business's 50 day moving average price is $141.38 and its 200-day moving average price is $132.39. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business's quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts anticipate that Gilead Sciences will post 8.62 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were given a dividend of $0.82 per share. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Friday, March 13th. Gilead Sciences's dividend payout ratio is presently 48.45%.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the insider directly owned 128,779 shares in the company, valued at $18,152,687.84. The trade was a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the chief financial officer owned 176,191 shares in the company, valued at $24,835,883.36. This represents a 1.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 168,640 shares of company stock worth $25,292,650 over the last ninety days. 0.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

Hedge funds have recently made changes to their positions in the company. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC raised its stake in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 85 shares during the last quarter. Corundum Trust Company INC purchased a new position in Gilead Sciences during the third quarter valued at $26,000. Quattro Advisors LLC purchased a new position in Gilead Sciences during the fourth quarter valued at $26,000. Finally, Wealth Preservation Advisors LLC raised its stake in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 81 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead completed the previously announced acquisition of Arcellx for ~$7.8B (cash + CVR), securing anito‑cel ahead of potential commercial launch — a clear strategic boost to Gilead’s cell‑therapy pipeline and commercial addressable market. Gilead Completes Acquisition of Arcellx
• Positive Sentiment: Technical analysts note GILD is retesting a long-term cup base breakout and could have significant upside if momentum holds — one firm projects as much as ~35% upside from current levels, which can attract momentum buyers. Gilead Crosses Critical Breakout Level
• Neutral Sentiment: Coverage noting the Arcellx close also flags that GILD recently tested near‑term technical support (around $128) and shows oversold momentum indicators — this can produce short‑term volatility even as the deal is digested. Blockonomi: Gilead Closes Arcellx Buyout
• Neutral Sentiment: Sector context: previews of Amgen’s Q1 and broader biotech ETF commentary provide mixed signals — positive drug growth themes offset by pricing pressure and biosimilar competition, which could moderate sector‑wide investor appetite. Amgen Q1 Preview
• Negative Sentiment: A shareholder resolution from AHF asks Gilead for greater transparency on patent exclusivities — this raises governance and IP‑risk scrutiny that could concern investors focused on long‑term revenue protections. AHF Shareholder Resolution

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.